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Abstract
There is a theoretical risk of adverse events following immunization with a preservative-
free, 2-dose vial formulation of 10-valent-pneumococcal conjugate vaccine (PCV10). We
set out to measure this risk. Four population-based surveillance sites in Kenya (total annual
birth cohort of 11,500 infants) were used to conduct a 2-year post-introduction vaccine
safety study of PCV10. Injection-site abscesses occurring within 7 days following vaccine
administration were clinically diagnosed in all study sites (passive facility-based surveil-
lance) and, also, detected by caregiver-reported symptoms of swelling plus discharge in
two sites (active household-based surveillance). Abscess risk was expressed as the num-
ber of abscesses per 100,000 injections and was compared for the second vs first vial dose
of PCV10 and for PCV10 vs pentavalent vaccine (comparator). A total of 58,288 PCV10
injections were recorded, including 24,054 and 19,702 identified as first and second vial
doses, respectively (14,532 unknown vial dose). The risk ratio for abscess following injec-
tion with the second (41 per 100,000) vs first (33 per 100,000) vial dose of PCV10 was 1.22
(95% confidence interval [CI] 0.37–4.06). The comparator vaccine was changed from a 2-
dose to 10-dose presentation midway through the study. The matched odds ratios for
abscess following PCV10 were 1.00 (95% CI 0.12–8.56) and 0.27 (95% CI 0.14–0.54)
when compared to the 2-dose and 10-dose pentavalent vaccine presentations, respec-
tively. In Kenya immunization with PCV10 was not associated with an increased risk of
injection site abscess, providing confidence that the vaccine may be safely used in Africa.
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The relatively higher risk of abscess following the 10-dose presentation of pentavalent vac-
cine merits further study.
Introduction
Globally, Streptococcus pneumoniae causes an estimated 14.5 million episodes of serious dis-
ease (including pneumonia, meningitis, and sepsis) and over 800,000 deaths annually in chil-
dren aged<5 years, with most pneumococcal-associated serious morbidity and mortality
occurring in low- and middle-income countries [1]. Since 2006, the World Health Organiza-
tion (WHO) has recommended that pneumococcal conjugate vaccine (PCV) be included in all
national immunization programs, particularly in countries with high child mortality (i.e.,
under 5 mortality rate of>50 deaths/1,000 births) [2–3]. The Kenya Ministry of Public Health
and Sanitation (MoPHS) applied for and received financial support from the GAVI Alliance to
introduce a 10-valent formulation of PCV (PCV10) manufactured by GlaxoSmithKline Vac-
cines (GSK).
In March 2009, GSK presented an application to the WHO prequalification committee for a
2-aliquot, preservative-free presentation of PCV10. (To avoid ambiguity, we hereafter refer to
the sequence of immunizations with the same antigen received by the same child as the “dose”
number and the sequence of volumes of vaccine withdrawn from a single vial as the “aliquot”
number. Thus, each child could receive 3 doses of PCV10 and each vial of PCV10 contained
two aliquots.) A preservative-free, multi-aliquot vial vaccine formulation had not previously
been used in developing countries. Theoretically, this formulation could result in adverse
events following immunization (AEFI) if the second aliquot became contaminated before use
—for example, if the second aliquot of PCV10 was not used within 6 hours of opening the vial.
Lacking data or experience from a developing country, the WHO pre-qualification committee
requested that the manufacturer work with an early-introduction developing country to char-
acterize the magnitude of AEFI risk associated with PCV10 following appropriate training of
the health workers who administer vaccines.
In late 2009, GSK agreed to fund two longstanding research collaborations with the Kenya
Medical Research Institute (KEMRI)—the KEMRI-Wellcome Trust Research Programme in
Kilifi and the KEMRI/Centers for Disease Control and Prevention (CDC) Research and Public
Health Collaboration in Nairobi and Kisumu—to conduct a two-year post-introduction, or
Phase IV, vaccine safety study of PCV10 in existing population-based health and demographic
surveillance platforms, referred to as the Vaccine Adverse Events in Kenya study (VAEIK). On
the basis of the establishment of this prospective safety study, the WHO pre-qualification com-
mittee approved the use of PCV10 in Kenya. Here, we report on the risks of injection site
abscess following immunization with second compared to first aliquots of PCV10 and with
PCV10 compared to pentavalent vaccine (the comparator) for the two-year VAEIK study
period, which concluded February 13, 2013.
Materials and Methods
Study Sites
The VAEIK study is a Phase IV study conducted at four sites: one site operated by the KEM-
RI-Wellcome Trust Programme—the Kilifi Health and Demographic Surveillance System
(HDSS) site at the Kenyan coast—and three sites operated by the KEMRI/CDC Research and
Public Health Collaboration—the Kibera population-based infectious disease surveillance
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(PBIDS) site in Nairobi, the Rarieda PBIDS site in western Kenya, and a portion of the
KEMRI/CDC HDSS site also in western Kenya and including parts of Rarieda and Siaya Dis-
tricts (Fig 1). The Rarieda PBIDS site is geographically embedded within the KEMRI/CDC
HDSS, but for purposes of this study, data reported for the KEMRI/CDC HDSS site do not
include data from Rarieda PBIDS. The four study sites have a combined annual birth cohort of
approximately 11,500 infants (Kilifi 9,000, Kibera 1,000, Rarieda 1,000, and the included por-
tion of the KEMRI/CDC HDSS 500 infants).
Kilifi HDSS site
The Kilifi HDSS has operated since the year 2000, and its population register is maintained by
visits to each household every four months [4]. All children born to mothers resident in the
Kilifi HDSS were included in the VAEIK study. In-migrating children aged<1 year also were
included in the VAEIK study if they fulfilled the criteria for residence, defined as a person who
intended to live at the address where he/she was found for at least 3 months, and who had
already spent at least one night at this address. As of March 2011, the Kilifi HDSS had a resi-
dent population of 261,919, including 10,681 infants aged<1 year. The complete (3-dose) pen-
tavalent vaccine coverage among children aged<1 year in the Kilifi HDSS was 91–96% [5] and
the infant mortality ratio (IMR) was 24.4/1,000 live births.
PBIDS sites in Kibera and Rarieda
Since 2005, KEMRI/CDC has operated PBIDS in a rural area of Rarieda District in western
Kenya and in a western section of the Kibera informal settlement in Nairobi, as described pre-
viously [6–7]. In both sites, PBIDS enrolled residents who had lived in the catchment area for
at least 4 months. To be enrolled in the Rarieda PBIDS site, adult participants also had to be
registered with the KEMRI/CDC HDSS. All infants born to mothers enrolled as participants in
PBIDS automatically were included in the VAEIK study unless the mothers requested other-
wise. In 2011, the Kibera PBIDS site had approximately 27,800 participants including 723
infants aged<1 year; the infant mortality rate was 50/1,000 person-years [8]. The Rarieda
PBIDS site had approximately 25,470 participants residing in 33 villages within Rarieda Dis-
trict in 2011, including 855 infants aged<1 year. In Rarieda in 2010, the complete pentavalent
vaccine coverage of infants aged<1 year was 85% and the IMR was 53/1,000 live births.
KEMRI/CDC HDSS site in western Kenya
Within a subset of the KEMRI/CDC HDSS in western Kenya, VAEIK study data were collected
at two health facilities in Siaya County: Ting’wang’i Health Centre (entire VAEIK study period)
and Njejra Health Centre (4 months, March-June 2011). The VAEIK study population
included infants enrolled in the KEMRI/CDC HDSS and residing in 26 villages within a 5 km
radius around Ting’wang’i Health Centre and 20 villages within a 3 km radius around Njejra
Health Centre in Siaya County. The KEMRI/CDC HDSS enrolled residents who had lived in
the catchment area for at least 4 months. Infants born to enrolled mothers automatically
became HDSS participants and were eligible for inclusion in the VAEIK study unless their
mothers requested otherwise. In 2011, the portion of the KEMRI/CDC HDSS included in the
VAEIK study had a total resident population of 17,200 and an annual birth cohort of 500
infants. In the overall KEMRI/CDC HDSS in 2010, the complete pentavalent vaccine coverage
of infants aged<1 year was 85% and the IMR was 67/1,000 live births.
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PCV10 Introduction in Kenya
PCV10 was officially introduced into the national immunization program in Kenya on Febru-
ary 14, 2011 with an active publicity campaign, and provided free of charge for infants coun-
try-wide. The vaccine booklet supplied by the Kenya MoPHS and training of immunization
workers stipulated that PCV10 would be administered in the right thigh while pentavalent vac-
cine (which contains diphtheria and tetanus toxoids, whole cell pertussis vaccine, H. influenzae
type b conjugate vaccine, and Hepatitis B vaccine delivered in a single needle) would be admin-
istered in the left thigh. The MoPHS policy indicated that each of these vaccines should be
given simultaneously to infants 6, 10 and 14 weeks of age. In addition, the MoPHS offered
catch-up vaccination, in 3 doses four weeks apart, to any child aged<12 months presenting to
Fig 1. Vaccine Adverse Events in Kenya (VAEIK) study sites.Map of Kenya showing VAEIK study sites (red circles). Abbreviations: CDC, Centers for
Disease Control and Prevention; HDSS, Health and Demographic Surveillance System; PBIDS, Population-based Infectious Disease Surveillance Site;
KEMRI, Kenya Medical Research Institute. Reprinted from original artist under a CC BY license, with permission from Alan Rubin, original copyright 2013.
doi:10.1371/journal.pone.0141896.g001
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a vaccine clinic during 2011. The MoPHS provided centralized, in-person training on PCV10
immunization practices to vaccinators in each district and distributed written guidance on cor-
rect handling and administration of PCV10. The MoPHS guidance informed vaccinators that
the PCV10 two-dose vial formulation lacked a preservative and instructed that opened vials
must be discarded at the end of each immunization session, or after 6 hours from first opening,
whichever came first. Vaccinators were not employed by the study projects at any of the
VAEIK sites, and VAEIK study staff did not provide any training or information to immuniza-
tion clinic personnel on infection control, appropriate vaccine handling or safe administration
of vaccines, thus ensuring real world conditions for the safety of the immunizations.
Inclusion Criteria
This report includes data from the entire two-year VAEIK study period: February 14, 2011
through February 13, 2013. In Kilifi, PCV10 was introduced on January 11, 2011, ahead of the
official national launch; thus, Kilifi HDSS data also include the period January 11 through Feb-
ruary 13, 2011. For a child to be included in the VAEIK study, he/she must have been aged<1
year and enrolled in HDSS or PBIDS surveillance in one of the study sites during the study
period.
Vaccine Surveillance and Aliquot Recording
Kilifi HDSS vaccine surveillance. In the Kilifi HDSS, a vaccine monitoring system existed
in all health facilities. Vaccine clinic data from the health facilities were entered into computers
directly at the point of immunization. The system captured information pertaining to child-
hood vaccines including all PCV10 doses given, date given and the number of the aliquot with-
drawn from the vaccine vial, as recorded in the Mother Child Booklet by the vaccinator, and
linked this directly to the population register of the Kilifi HDSS.
KEMRI/CDC HDSS vaccine surveillance. In the KEMRI/CDC HDSS site in western
Kenya, vaccine clinic data were collected for purposes of the VAEIK study at Njejra and Ting’-
wang’i Health Centres. In addition, vaccination history was recorded for all HDSS children
aged<2 years at household visits conducted every 4 months. At home visits, the preferred
source of vaccine history data was the Mother Child Booklet, but verbal reports from caregivers
also were accepted if the booklet was unavailable. Aliquot information for PCV10 was recorded
in Mother Child Booklets by the vaccinators and abstracted by HDSS surveillance staff.
Rarieda & Kibera PBIDS vaccine surveillance. The Rarieda PBIDS site in western Kenya
was embedded within the KEMRI/CDC HDSS, and vaccination history information collected
during 4-monthly HDSS home visits were linked to PBIDS participants. In the Rarieda PBIDS
site, vaccination data were obtained during immunization visits to the PBIDS study facility,
Lwak Mission Hospital, and 5 other clinics. In addition, in both the Rarieda and Kibera PBIDS
sites, routine household visits to collect morbidity data were conducted weekly (February
through June 2011) or biweekly (beginning in July 2011) throughout the study period. At each
home visit, community interviewers (CIs) recorded all vaccines received by children in the
household since the previous home visit. As in the KEMRI/CDC HDSS, the preferred source of
vaccine history data was the Mother Child Booklet, but verbal reports also were accepted if nec-
essary. In the Kibera PBIDS site, vaccination data also were obtained during immunization vis-
its to the PBIDS study facility, Tabitha Clinic. Vaccination data obtained during home and
facility visits in the KEMRI/CDC HDSS and PBIDS sites included the date of vaccination, the
dose number, the injection site, and the number of the aliquot withdrawn from the vaccine
vial, as recorded in the Mother Child Booklet.
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Ascertainment of Injection Site Abscesses
Abscesses were detected through facility- and household-based surveillance in the two PBIDS
sites, but only through facility-based surveillance in the two HDSS sites.
Facility-based abscess surveillance in Kilifi HDSS, KEMRI/CDC HDSS, and the two
PBIDS sites. In all study sites, caregivers could bring a child with suspected AEFI, such as
injection site abscess, back to the Maternal and Child Health (MCH) clinic or other vaccine
delivery center where the vaccine was administered. All children aged<1 year with history of
vaccination in the 7 days before the sick visit were assessed for possible AEFI if the presenting
complaint included localized symptoms in an extremity (other than obvious trauma), and/or if
the caregiver suspected the child had AEFI, and/or if the clinician suspected toxic shock syn-
drome. In all sites, a standardized form was used to capture demographic and clinical informa-
tion, including vaccine history, reported local and systemic symptoms, physical examination
findings (including detailed evaluation of injection site(s) for swelling [diameter was measured
and recorded], induration, fluctuance, erythema, discharge, local hotness, blisters, red streaks,
or swollen regional lymph nodes), circumference of right and left thighs (if there was history of
thigh vaccination), interventions/treatments provided (such as surgical drainage, antibiotics, or
anti-inflammatory/anti-pyretic medications), results of laboratory evaluations, if any, outcome
of clinical encounter, and clinical impression, such as injection site abscess. Depending on
symptom severity, MCH clinics could refer patients with suspected AEFI to a hospital for fur-
ther evaluation.
In the Kilifi HDSS site, data were recorded on facility-based questionnaires by medical staff
at any one of 26 health centers within the Kilifi HDSS. Data were checked on-site by the Kilifi
VAEIK study project manager and scanned copies of completed facility-based questionnaires
were stored. In study health facilities in the KEMRI/CDC HDSS (Njejra and Ting’wang’i
Health Centres), Rarieda PBIDS (Lwak Mission Hospital) and Kibera PBIDS (Tabitha Clinic)
surveillance sites, trained study clinicians entered data on suspected AEFI onto scannable
paper forms.
Household-based abscess surveillance in the two PBIDS sites. Household-based detec-
tion of abscesses occurred in the Rarieda and Kibera PBIDS surveillance sites. Trained CIs vis-
ited the homes of all PBIDS participants weekly (through June 2011) or once every two weeks
(beginning July 2011), and used personal digital assistants or smart phones to administer stan-
dard questions about vaccine history and morbidity [6]. If a caregiver reported that a child
received an immunization since the last home visit, the caregiver was asked whether injection
site inflammation was observed following the immunization. From February through June
2011, the caregiver was only asked to report injection site inflammation that occurred within 7
days after immunization, but beginning in July 2011 the caregiver was asked to report injection
site inflammation occurring within 14 days after immunization and the date(s) when the injec-
tion site symptoms began. If injection site inflammation was reported, the caregiver was asked
to report the presence or absence (and if present, the location and dates) of injection site swell-
ing, redness, discharge, or other local symptoms (referred to collectively as “abscess related
symptoms”). Information on systemic symptoms, such as subjective fever, were collected for
all participants at every home visit. Children with reported injection site inflammation were
referred to the local study health facility (Tabitha Clinic in Kibera and Lwak Mission Hospital
in Rarieda District) for further evaluation.
Abscess definition, standardization and training. An injection site abscess is a localized
soft tissue collection of material, occurring at the site of immunization [9]. For purposes of this
study, two injection site abscess case definitions were used. First, in all of the study facilities,
an injection site abscess was clinically diagnosed by the treating health care worker based on
Risk of PCV10 Injection-Site Abscess in Kenya
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clinician’s judgment. Although laboratory tests such as full hemogram and blood cultures can
be helpful to inform the management of an abscess, these were not frequently performed as
part of routine care in the study areas; thus, laboratory criteria were not included in the case
definition of an injection site abscess for this study. Rather, clinicians diagnosed injection site
abscess using history and physical exam findings, in accordance with standardized training
(described below). Second, for the household-based surveillance conducted in the two PBIDS
sites, where no clinician was present, we used a modified version of a clinical case definition of
injection site abscess from consensus guidelines published in 2007 by the Brighton Collabora-
tion Local Reactions Working Group for Abscess at Injection Site [8], as follows: Mass or swell-
ing at injection site AND spontaneous drainage of material.
Health workers (including clinical officers, medical officers and nurses) in all study sites
received training on intramuscular abscess identification and management conducted by a
pediatric surgeon from the University of Nairobi School of Medicine. In all study sites, health
workers and data entry staff were trained on how to complete the VAEIK AEFI case report
form used in the health facility-based surveillance. Monthly (KEMRI/CDC HDSS and PBIDS
sites) or quarterly (Kilifi HDSS site) refresher trainings, specific to each site, were conducted,
and in all sites, health workers were encouraged to complete both the Kenya MoPHS AEFI
form and the VAEIK study case report form for all adverse events reported.
Statistical Analysis
Analyses of main objectives. The primary objective was to evaluate whether the site of
injection of a second aliquot of PCV10 was more likely to develop an abscess or related symp-
toms within 7 days than the site of injection of a first aliquot of PCV10. The 7-day time lag was
chosen to optimize the specificity of the AEFI endpoint by restricting to events occurring
within a short period of time following immunization. Specificity also was enhanced by limit-
ing surveillance of abscess events to the appropriate thigh that received the vaccine injection.
For the primary objective, we computed risk ratios (RRs) using log binomial regression.
Ninety-five percent confidence intervals (CIs) and the corresponding p-values were calculated
with generalized estimating equations using an exchangeable correlation structure to account
for intra-child correlation in injection site abscesses or related symptoms. An additional objec-
tive was to evaluate whether an injection site in the leg that received PCV10 was more likely to
develop an abscess or related symptoms within 7 days than an injection site in the leg that
received pentavalent vaccine. The Mother Child Booklet contained pre-printed instructions
directing vaccinators to place PCV10 only into the right thigh, and training provided by the
MoPHS at the time of PCV10 introduction instructed vaccinators to place pentavalent vaccine
only into the left thigh; for VAEIK analyses, correct vaccine placement was assumed. Exact
conditional logistic regression was used to calculate matched odds ratios (mORs) and p-values
to evaluate abscess risk among matched pairs of PCV10 and pentavalent vaccine injections
received at the same immunization encounter; 95% CIs were obtained using the asymptotic
method. Fisher’s exact test was used for risk comparisons with small cell sizes (<5). All analy-
ses were performed in SAS version 9.2 (SAS Institute, Cary, North Carolina, USA).
Analyses related to different pentavalent vaccine formulations. Pentavalent vaccine was
selected as the comparator because it was given according to the same 3-dose schedule as
PCV10 and both vaccines were administered in a thigh. In addition, the GSK pentavalent vac-
cine Tritanrix™-HepB/Hiberix™ (presented as a 2-aliquot vial with the preservative thimerosal,
and consisting of a liquid and freeze dried component which are mixed immediately prior to
immunization) already was established in Kenya’s routine immunization program at the time
of PCV10 introduction and was considered to have an acceptable safety profile. However, in
Risk of PCV10 Injection-Site Abscess in Kenya
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July 2011, the Kenya Expanded Programme on Immunization initiated a switch from the
GSK pentavalent vaccine to a Serum Institute of India (SII) pentavalent vaccine product (pre-
sented as a 10-aliquot vial with thimerosal). Within 3 months of introduction, all pentavalent
immunizations delivered through Kenya’s routine immunization program used the new SII
formulation.
Following the introduction of the new presentation of pentavalent vaccine, we noticed an
increase in the frequency of reporting of abscesses in the control group and decided therefore
to do an ad hoc analysis to compare observed risks of abscess or related symptoms between
the two pentavalent vaccine formulations using data from the Kilifi HDSS, Rarieda PBIDS,
and KEMRI/CDC HDSS sites. Data from the Kibera PBIDS site were not included in this
analysis because Kibera PBIDS records did not distinguish whether observed abscesses or
related symptoms occurred at a PCV10 injection site or a pentavalent vaccine injection site
from February 2011 through July 2011 (i.e. whether the abscess was located on the left or
right leg), limiting data available for analysis from the GSK pentavalent vaccine period. We
also compared risks of abscess and related symptoms for PCV10 separately to each pentava-
lent vaccine formulation.
Ethics Statement
The VAEIK protocol was reviewed and approved by KEMRI’s Ethical Review Committee
(KEMRI #1873) and the Oxford Tropical Research Ethics Committee (#48–10). CDC’s Institu-
tional Review Board approved the VAEIK protocol as non-research; the home-visit assessment
of abscesses in Kibera and Rarieda was approved within an amendment to the PBIDS protocol
(KEMRI #1899, CDC protocol #4566). Data collected in the KEMRI/CDC HDSS were
approved through the HDSS protocol (KEMRI #1801, CDC #3308). Parents or guardians of all
participants provided written informed consent to participate in surveillance of abscess-related
health outcomes following immunization, as approved under the respective site protocols
(KEMRI #1899/CDC #4566 for Kibera and Rarieda PBIDS sites; KEMRI #1801/CDC #3308 for
KEMRI/CDC HDSS site; KEMRI #1873 for Kilifi HDSS site). Written informed consent for
recording of vaccination history also was provided by parents or guardians in the KEMRI/
CDC HDSS site and both PBIDS sites under the same approved protocols used for abscess sur-
veillance. In the Kilifi HDSS, vaccine history monitoring was conducted by staff of the Kenya
MOPHS under the Pneumococcal Conjugate Vaccine Impact Study (KEMRI #1433); the
KEMRI Ethical Review Committee determined this vaccine history monitoring to be public
health surveillance which did not require individual informed consent.
Results
Vaccine Dose and Aliquot Counts
A total of 58,288 doses of PCV10 and 46,265 doses of pentavalent vaccine were administered to
enrolled infants at all four sites during the VAEIK study period (Table 1). The largest share of
PCV10 (87.5%) and pentavalent vaccine (86.6%) doses were administered to children from the
Kilifi HDSS. Overall, aliquot information was available for 43,756 (75.1%) PCV10 injections,
and of these 24,054 (55.0%) were first aliquots and 19,702 (45.0%) were second aliquots
(Table 2). The completeness of aliquot recording improved substantially from the first year
(67.3%) to the second year (98.4%) of the VAEIK study among facilities documenting PCV10
aliquot number (data not shown).
Risk of PCV10 Injection-Site Abscess in Kenya
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PCV10 Abscess Risk by Aliquot Number
Among all study sites, a total of 16 injection-site abscesses were identified within 7 days follow-
ing injections of PCV10 for which aliquot number was recorded (Table 3). Overall, there was
no statistically significant difference in risk of abscess following injection with the second (8
abscesses, 41 abscesses per 100,000 injections) compared to the first (8 abscesses, 33 abscesses
per 100,000 injections) aliquot of PCV10 (RR 1.22, 95% confidence interval [CI] 0.37–4.06).
Table 1. Number of pneumococcal conjugate vaccine (PCV10) and pentavalent vaccine immunizations administered to infants in VAEIK study
sites according to dose number, Kenya, 14 February 2011–13 February 2013.
Study site and dose numbera No. of Immunizations
14 Feb 2011–13 Feb 2012 14 Feb 2012–13 Feb 2013 Total
PCV Pentavalent Vaccine PCV Pentavalent Vaccine PCV Pentavalent Vaccine
Kiliﬁ HDSSb
Dose 1 12,846 7,625 5,857 5,918 18,703 13,543
Dose 2 11,292 7,728 5,595 5,651 16,887 13,379
Dose 3 9,871 7,428 5,537 5,730 15,408 13,158
Total 34,009 22,781 16,989 17,299 50,998 40,080
Kibera PBIDS
Dose 1 734 509 356 350 1,090 859
Dose 2 592 408 283 285 875 693
Dose 3 478 369 291 290 769 659
Unknown dose 6 2 6 7 12 9
Total 1,810 1,288 936 932 2,746 2,220
Rarieda PBIDS
Dose 1 548 443 425 433 973 876
Dose 2 539 401 392 399 931 800
Dose 3 389 343 370 372 759 715
Total 1,476 1,187 1,187 1,204 2,663 2,391
KEMRI/CDC HDSS
Dose 1 400 286 263 256 663 542
Dose 2 391 273 253 252 644 525
Dose 3 315 249 259 258 574 507
Total 1,106 808 775 766 1,881 1,574
All study sites
Dose 1 14,528 8,863 6,901 6,957 21,429 15,820
Dose 2 12,814 8,810 6,523 6,587 19,337 15,397
Dose 3 11,053 8,389 6,457 6,650 17,510 15,039
Unknown dose 6 2 6 7 12 9
Total 38,401 26,064 19,887 20,201 58,288 46,265
Abbreviations: CDC, Centers for Disease Control and Prevention; HDSS, Health and Demographic Surveillance System; PBIDS, Population-based
Infectious Disease Surveillance Site; KEMRI, Kenya Medical Research Institute; VAEIK, Vaccine Adverse Events in Kenya
a
“Dose number” refers to the ordinal number of a vaccination within the 3-dose series for PCV or pentavalent vaccine—the ﬁrst vaccination of a given
child with PCV was termed “dose 1,” the second vaccination of the same child with PCV was termed “dose 2,” and the third vaccination of the same child
with PCV was termed “dose 3” (likewise for pentavalent vaccine).
bKiliﬁ HDSS data include 5,232 doses of PCV (4,971 dose 1; 261 dose 2) and 2,118 doses of pentavalent vaccine (628 dose 1; 801 dose 2; 689 dose 3)
administered from 11 Jan 2011–13 Feb 2011.
doi:10.1371/journal.pone.0141896.t001
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Table 2. Number of pneumococcal conjugate vaccine (PCV10) immunizations administered to infants
in VAEIK study sites according to aliquot number, Kenya, 14 February 2011–13 February 2013.
Study site and aliquot numbera No. of Immunizations
14 Feb 2011–13 Feb 2012 14 Feb 2012–13 Feb 2013 Total
Kiliﬁ HDSSb
Aliquot 1 12,254 9,254 21,508
Aliquot 2 10,117 7,663 17,780
Unknown aliquot 11,638 72 11,710
% Unknown 34.2% 0.42% 23.0%
Total 34,009 16,989 50,998
Kibera PBIDSc
Aliquot 1 342 170 512
Aliquot 2 256 104 360
Unknown aliquot 1,212 662 1,874
% Unknown 67.0% 70.7% 68.2%
Total 1,810 936 2,746
Rarieda PBIDSc
Aliquot 1 478 523 1,001
Aliquot 2 409 395 804
Unknown aliquot 589 269 858
% Unknown 39.9% 22.7% 32.2%
Total 1,476 1,187 2,663
KEMRI/CDC HDSS
Aliquot 1 597 436 1,033
Aliquot 2 427 331 758
Unknown aliquot 82 8 90
% Unknown 7.4% 1.0% 4.8%
Total 1,106 775 1,881
All study sites
Aliquot 1 13,671 10,383 24,054
Aliquot 2 11,209 8,493 19,702
Unknown aliquot 13,521 1,011 14,532
% Unknown 35.2% 5.1% 24.9%
Total 38,401 19,887 58,288
Abbreviations: CDC, Centers for Disease Control and Prevention; HDSS, Health and Demographic
Surveillance System; PBIDS, Population-based Infectious Disease Surveillance Site; KEMRI, Kenya
Medical Research Institute; VAEIK, Vaccine Adverse Events in Kenya
a
“Aliquot number” refers to the order in which quantities of vaccine were removed from a multidose vial for
administration to a child—the ﬁrst quantity of vaccine removed from a given vial was termed “aliquot 1” and
the second quantity removed from the same vial was termed “aliquot 2.”
bKiliﬁ HDSS data include 5,232 doses of PCV (36 aliquot 1; 6 aliquot 2; 5,190 unknown aliquot)
administered from 11 Jan 2011–13 Feb 2011.
cData shown are for all health facilities in each PBIDS. However, only a subset of facilities participated in
recording aliquot information. Of the total doses of PCV administered in each PBIDS site, 35.8% and
86.2% were administered in aliquot recording facilities in Kibera and Rarieda, respectively. Among the
facilities that recoded aliquot information, the overall percentage of unknown aliquots was 11.4% in the
Kibera PBIDS site and 21.4% in the Rarieda PBIDS site.
doi:10.1371/journal.pone.0141896.t002
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There also were no significant differences in risks of abscess or related symptoms (PBIDS sites)
according to PCV10 aliquot number in individual study sites (Table 3).
Abscess Risk of PCV10 Compared to Pentavalent Vaccines
Among a total of 38,958 matched vaccination encounters in which the infant received both
PCV10 and pentavalent vaccine, 17 injection site abscesses were identified within 7 days fol-
lowing PCV10 injection (44/100,000 injections) and 43 abscesses were identified within 7 days
following pentavalent vaccine injection (110/100,000 injections; matched odds ratio [mOR]
0.30, 95% CI 0.16–0.58; p = 0.0002) (Table 4). Across sites, PCV10-related injection site
abscesses ranged from zero in the KEMRI/CDC HDSS site and the Kibera PBIDS site to 14 in
the Rarieda PBIDS site, and pentavalent vaccine-related abscesses ranged from zero in the
KEMRI/CDC HDSS site to 25 in the Rarieda PBIDS site. Compared to pentavalent vaccine,
PCV10 was associated with statistically significantly lower risk of injection site abscess in the
Kilifi HDSS (mOR 0.17, 95% CI 0.04–0.75), of care-giver reported injection site swelling in
both PBIDS sites (Kibera: mOR 0.30, 95% CI 0.20–0.46; Rarieda: mOR 0.27, 95% CI 0.22–
0.32), and of caregiver-reported discharge (mOR 0.43, 95% CI 0.22–0.85) and redness (mOR
0.30, 95% CI 0.21–0.44) in the Rarieda PBIDS site.
Table 3. Risk of developing abscess or similar symptomswithin 7 days in relation to pneumococcal conjugate vaccine (PCV10) injection, accord-
ing to whether the child received a first or second aliquot of PCV in VAEIK study sites, Kenya, 14 February 2011–13 February 2013.
Study site and syndrome 1st Aliquot 2nd Aliquot Risk Ratio
n Na n/N per 100,000 n Na n/N per 100,000 2nd/1st Aliquot 95% CI p-value
Kiliﬁ HDSSb
Abscess 2 21,508 9 1 17,780 6 0.60 [0.05–6.67] 0.68
Kibera PBIDSc,d
Abscess 0 344 0 0 200 0 - - -
Swelling 21 344 6,105 11 200 5,500 0.90 [0.46–1.78] 0.76
Discharge 1 344 291 0 200 0 0.00 - 1.00
Redness 13 344 3,779 4 200 2,000 0.53 [0.16–1.76] 0.30
Rarieda PBIDSd
Abscess 6 1,001 599 7 804 871 1.45 [0.36–5.90] 0.60
Swelling 228 1,001 22,777 189 804 23,507 1.03 [0.88–1.22] 0.71
Discharge 8 1,001 799 8 804 995 1.25 [0.36–4.31] 0.73
Redness 22 1,001 2,198 23 804 2,861 1.30 [0.72–2.35] 0.38
KEMRI/CDC HDSS
Abscess 0 1,033 0 0 758 0 - - -
All study sites
Abscess 8 23,886 33 8 19,542 41 1.22 [0.37–4.06] 0.74
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, conﬁdence interval; HDSS, Health and Demographic Surveillance System; PBIDS,
Population-based Infectious Disease Surveillance Site; KEMRI, Kenya Medical Research Institute; VAEIK, Vaccine Adverse Events in Kenya
aDenominator is the number of vaccine doses administered.
bDenominators for Kiliﬁ HDSS include 36 1st aliquots and 6 2nd aliquots administered from 11 Jan 2011–13 Feb 2011; no abscess events following PCV
injection occurred during this time period.
cExcludes observations for the period from February 2011 through June 2011 because it was not documented whether syndromes were related to PCV
injection sites or to pentavalent vaccine injection sites during this period.
dPBIDS data represent household- and health facility-based surveillance combined; no abscesses or related symptoms were identiﬁed at the PBIDS
health facilities.
doi:10.1371/journal.pone.0141896.t003
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The risks of abscess per 100,000 injections for the SII versus GSK pentavalent vaccines were,
respectively, 44 and 0 in the Kilifi HDSS site (RR1, p = 0.088), 1,304 and 363 in the Rarieda
PBIDS site (RR 3.55, 95% CI 0.47–26.92, p = 0.22), and 108 and 22 across all study sites except
the Kibera PBIDS site (RR 4.84, 95% CI 0.66–35.64, p = 0.12) (Table 5). In matched analyses
stratified by pentavalent vaccine formulation, risk of abscess did not differ significantly
between PCV10 and GSK pentavalent vaccine in the two HDSS sites (risk zero per 100,000
injections for both vaccines in both sites) or the Rarieda PBIDS site (risk 475 and 475 per
100,000 injections for PCV10 and GSK pentavalent vaccine, respectively; mOR 1.00, 95% CI
0.12–8.56) (Table 6). For data combined across all sites, abscess risk was significantly lower for
PCV10 (47 abscesses per 100,000 injections) than for SII pentavalent vaccine (128 abscesses
per 100,000 injections; mOR 0.27, 95% CI 0.14–0.54) (Table 7). Caregiver-reported injection
site swelling was significantly less common following immunization with PCV10 than with
either pentavalent vaccine formulation (Tables 6 and 7).
Discussion
In this 2-year, multisite Phase IV study, we did not find evidence of increased risk of injection
site abscess following infant immunization with the second compared to the first aliquot of a
2-aliquot, preservative-free formulation of 10-valent pneumococcal conjugate vaccine intro-
duced into Kenya’s routine immunization program in 2011. Further, no increased risk of
Table 4. Matched analysis of the risk of developing abscess or similar symptomswithin 7 days in relation to pneumococcal conjugate vaccine
(PCV10) injection and pentavalent (combined GSK & SII) vaccine injection in VAEIK study sites, Kenya, 14 February– 13 February 2013.
Study site and syndrome GSK & SII-pentavalent Vaccine PCV
n Na n/N per 100,000 n Na n/N per 100,000 OR 95% CI p-value
Kiliﬁ HDSS
Abscess 13 33,724 39 3 33,724 9 0.17 [0.04–0.75] 0.0129
Kibera PBIDSb
Abscess 5 1,577 317 0 1,577 0 0.00 - 0.0623
Swelling 158 1,577 10,019 97 1,577 6,151 0.30 [0.20–0.46] < .0001
Discharge 5 1,577 317 5 1,577 317 1.00 [0.17–5.99] 1.0000
Redness 48 1,577 3,044 44 1,577 2,790 0.73 [0.33–1.59] 0.5483
Rarieda PBIDSb
Abscess 25 2,182 1,146 14 2,182 642 0.46 [0.21–0.98] 0.0616
Swelling 810 2,182 37,122 491 2,182 22,502 0.27 [0.22–0.32] < .0001
Discharge 34 2,182 1,558 19 2,182 871 0.43 [0.22–0.85] 0.0201
Redness 132 2,182 6,049 57 2,182 2,612 0.30 [0.21–0.44] < .0001
KEMRI/CDC HDSS
Abscess 0 1,475 - 0 1,475 0 - - -
All study sites
Abscess 43 38,958 110 17 38,958 44 0.30 [0.16–0.58] 0.0002
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, conﬁdence interval; GSK, GlaxoSmithKline; HDSS, Health and Demographic
Surveillance System; PBIDS, Population-based Infectious Disease Surveillance Site; KEMRI, Kenya Medical Research Institute; OR, odds ratio; SII,
Serum Institute of India; VAEIK, Vaccine Adverse Events in Kenya
aDenominator is the number of vaccine doses administered. Data represent matched vaccine encounters in which the infant received both pentavalent
vaccine and PCV10 at the same visit.
bPBIDS data represent household- and health facility-based surveillance combined; no abscesses or related symptoms were identiﬁed at the PBIDS
health facilities.
doi:10.1371/journal.pone.0141896.t004
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abscesses was seen following PCV10 compared to pentavalent vaccine (either formulation)
administered according to the same 3-dose schedule as PCV10. To our knowledge, this was the
first and to-date is the longest Phase IV study of a multi-aliquot, preservative-free vaccine for-
mulation used routinely in a developing country, and our findings suggest that 2-aliquot vial
formulations of such vaccines have the potential for safe use in developing country settings,
assuming adherence to policies regarding storage and use. We made the incidental observation
that the risk of abscess following the 10-dose formulation of pentavalent vaccine was higher
than the risk following the 2-dose formulation. This difference was large but it was not statisti-
cally significant. Our finding that the 2-aliquot, preservative-free formulation of PCV10 has
been safely introduced in Kenya is important because it supports introduction of this vaccine
in other developing countries where pneumococcal immunization may substantially reduce
morbidity and mortality from pneumococcal disease among young children [10–11].
For our primary analysis, evaluating the abscess risk of second compared to first aliquot
injections of PCV10, the study had sufficient power to detect only large effect sizes. We calcu-
late that all study sites combined had 86% power to detect a risk ratio of 3.5 but only 56%
power to detect a risk ratio of 2.5 for abscesses associated with aliquot 2 when compared with
aliquot 1. Smaller differences in abscess risk between PCV10 aliquots 1 and 2 might not have
been detected because of insufficient sample size. To detect a 2-fold increased risk—which
would be of considerable public health importance—the study would need to have been 2.4
times larger overall. Encouragingly, a one-year study of PCV10 AEFI in Ethiopia that was pat-
terned on VAEIK methods also found no statistically significant increased risk of injection site
abscess following immunization with the second compared to the first aliquot of PCV10 [12].
The comparison of abscess and related symptom risks of PCV10 and pentavalent vaccine
was complicated by the change in the formulation of pentavalent vaccine used in Kenya’s
Table 5. Risk of developing abscess or similar symptomswithin 7 days in relation to SII-pentavalent vaccine injection or GSK-pentavalent vaccine
injection in VAEIK study sites, Kenya, 14 February 2011–13 February 2013.
Study site and syndrome GSK-pentavalent Vaccine (2-dose
vial)
SII-pentavalent Vaccine (10-dose
vial)
Risk Ratio 95% CI p-value
n Na n/N per 100,000 n Na n/N per 100,000
Kiliﬁ HDSS
Abscess 0 8,045b 0 14 32,035 44 1 - 0.088
Rarieda PBIDSc
Abscess 2 551 363 24 1,840 1,304 3.55 [0.47–26.92] 0.22
Swelling 191 551 34,664 680 1,840 36,957 1.07 [0.91–1.25] 0.43
Discharge 4 551 726 32 1,840 1,739 2.38 [0.56–10.19] 0.24
Redness 37 551 6,715 109 1,840 5,924 0.88 [0.57–1.37] 0.58
KEMRI/CDC HDSS
Abscess 0 350 0 0 1224 0 - - -
All sites
Abscess 2 8,946 22 38 35,099 108 4.84 [0.66–35.64] 0.12
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, conﬁdence interval; GSK, GlaxoSmithKline; HDSS, Health and Demographic
Surveillance System; PBIDS, Population-based Infectious Disease Surveillance Site; KEMRI, Kenya Medical Research Institute; SII, Serum Institute of
India; VAEIK, Vaccine Adverse Events in Kenya
aDenominator is the number of vaccine doses administered.
bIncludes 2,118 doses of GSK-pentavalent vaccine administered from 11 Jan 2011–13 Feb 2011.
cPBIDS data represent household- and health facility-based surveillance combined; no abscesses or related symptoms were identiﬁed at the PBIDS
health facility.
doi:10.1371/journal.pone.0141896.t005
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routine immunization program during the study period, from a 2-aliquot presentation manu-
factured by GSK to a 10-aliquot presentation manufactured by the Serum Institute of India.
Because of the potential difference in abscess risks related to the two pentavalent vaccine for-
mulations, we performed stratified analyses comparing PCV10 abscess risk separately to the
GSK and SII pentavalent vaccine products, in addition to the planned comparison of abscess
risk between PCV10 and pentavalent vaccine over the entire 2-year study period. None of
these analyses showed increased risk of abscess following immunization with PCV10 compared
to the pentavalent vaccine products, providing reassurance that the preservative-free 2-aliquot
vial formulation of PCV10 may be used safely in Kenya. Nevertheless, the power of the study
to detect differences in vaccine safety between PCV10 and the originally intended comparator,
the GSK pentavalent vaccine, was reduced in the stratified analysis.
Given the heterogeneity in our surveillance methods (active versus passive surveillance), dif-
ferences in risk estimates across sites, and a lack of external validation of our abscess case defi-
nitions, a concern might exist that our failure to find an increased abscess risk for the second
compared to first aliquot of PCV10 could reflect bias toward the null resulting from nondiffer-
ential misclassification errors related to exposures and/or outcomes. We do not have informa-
tion on the frequency of potential misclassification of the first versus second aliquot of PCV10,
which could have reduced the observed effect sizes. However, the incidental observation of an
increased abscess risk of the SII compared to GSK pentavalent vaccine confirms the potential
of the surveillance methodology to detect systematic differences in abscess risk for products
within Kenya’s routine immunization program. Thus, as the VAEIK study did have the capac-
ity to identify programmatic associations between specific vaccine exposures and risks of
Table 6. Matched analysis of the risk of developing abscess or similar symptomswithin 7 days in relation to pneumococcal conjugate vaccine
(PCV10) injection and GSK-pentavalent vaccine injection in VAEIK study sites, Kenya, 14 February 2011–13 February 2013.
Study site and syndrome GSK-pentavalent Vaccine PCV
n Na n/N per 100,000 n Na n/N per 100,000 OR 95% CI p-value
Kiliﬁ HDSSb
Abscess 0 6,271 0 0 6,271 0 - -
Rarieda PBIDSc
Abscess 2 421 475 2 421 475 1.00 [0.12–8.56] 1.0000
Swelling 160 421 38,005 123 421 29,216 0.49 [0.33–0.73] 0.0004
Discharge 3 421 713 3 421 713 1.00 [0.16–6.14] 1.0000
Redness 29 421 6,888 17 421 4,038 0.49 [0.24–0.98] 0.0597
KEMRI/CDC HDSS
Abscess 0 267 - 0 267 0 -
All study sites
Abscess 2 6,959 29 2 6,959 29 1.00 [0.12–8.56] 1.000
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, conﬁdence interval; GSK, GlaxoSmithKline; HDSS, Health and Demographic
Surveillance System; PBIDS, Population-based Infectious Disease Surveillance Site; KEMRI, Kenya Medical Research Institute; OR, odds ratio; VAEIK,
Vaccine Adverse Events in Kenya
aDenominator is the number of vaccine doses administered. Data represent matched vaccine encounters in which the infant received both pentavalent
vaccine and PCV10 at the same visit.
bDenominators for Kiliﬁ HDSS include 1,719 matched doses of PCV and GSK-pentavalent vaccine administered from 11 Jan 2011–13 Feb 2011.
cPBIDS data represent household- and health facility-based surveillance combined; no abscesses or related symptoms were identiﬁed at the PBIDS
health facility.
doi:10.1371/journal.pone.0141896.t006
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injection site abscess, it is likely that the study would have identified similar excess risk related
to the second aliquot of PCV10, if one had existed.
Our estimates of abscess risk should be interpreted in light of the different surveillance prac-
tices used across sites. Active surveillance, which was used only in the two PBIDS sites, is nor-
mally associated with higher ascertainment of AEFIs, especially for mild symptoms. This is
likely to account for our findings that the estimates of abscess risk following immunization
were 10–100 times greater in the PBIDS sites compared to the Kilifi HDSS site. Despite stan-
dard training in the recognition and case-definition of abscess at each study site, inherent dif-
ferences between active and passive surveillance processes raise the possibility that the clinical
entities classified as abscess may also have differed across sites.
We incidentally observed that the risk of abscess was 4.8-fold higher across study sites fol-
lowing immunization with the 10-aliquot vial SII pentavalent vaccine formulation compared
to the 2-aliquot vial GSK pentavalent vaccine formulation. This association was not statistically
significant and could have resulted from sampling error. The association most closely
approached statistical significance in the Kilifi HDSS site (p = 0.088), which contributed the
largest share of vaccine observations among the four study sites. It also is possible that some
proportion of the observed difference in abscess risk for the SII versus GSK pentavalent vaccine
could have resulted from increased sensitivity of VAEIK surveillance procedures over time, or
from other aspects of the VAEIK study design that were not tailored to properly evaluate the
Table 7. Matched analysis of the risk of developing abscess or similar symptomswithin 7 days in relation to pneumococcal conjugate vaccine
(PCV10) injection and SII-pentavalent vaccine injection in VAEIK study sites, Kenya, 14 February 2011–13 February 2013.
Study site and syndrome SII-pentavalent Vaccine PCV
n Na n/N per 100,000 n Na n/N per 100,000 OR 95% CI p-value
Kiliﬁ HDSS
Abscess 13 27,453 47 3 27,453 11 0.17 [0.04–0.75] 0.0129
Kibera PBIDSb
Abscess 5 1,577 317 0 1,577 0 0.00 - 0.0623
Swelling 158 1,577 10,019 97 1,577 6,151 0.30 [0.20–0.46] < .0001
Discharge 5 1,577 317 5 1,577 317 1.00 [0.17–5.99] 1.0000
Redness 48 1,577 3,044 44 1,577 2,790 0.73 [0.33–1.59] 0.5483
Rarieda PBIDSb
Abscess 23 1,761 1,306 12 1,761 681 0.41 [0.18–0.93] 0.0465
Swelling 650 1,761 36,911 368 1,761 20,897 0.22 [0.18–0.27] < .0001
Discharge 31 1,761 1,760 16 1,761 909 0.37 [0.18–0.79] 0.0123
Redness 103 1,761 5,849 40 1,761 2,271 0.25 [0.16–0.40] < .0001
KEMRI/CDC HDSS
Abscess 0 1,208 - 0 1,208 0 - - -
All study sites
Abscess 41 31,999 128 15 31,999 47 0.27 [0.14–0.54] 0.0001
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, conﬁdence interval; HDSS, Health and Demographic Surveillance System; PBIDS,
Population-based Infectious Disease Surveillance Site; KEMRI, Kenya Medical Research Institute; OR, odds ratio; SII, Serum Institute of India; VAEIK,
Vaccine Adverse Events in Kenya
aDenominator is the number of vaccine doses administered. Data represent matched vaccine encounters in which the infant received both pentavalent
vaccine and PCV10 at the same visit.
bPBIDS data represent household- and health facility-based surveillance combined; no abscesses or related symptoms were identiﬁed at the PBIDS
health facilities.
doi:10.1371/journal.pone.0141896.t007
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safety of the change in pentavalent vaccine formulation. There may have been misclassification
of exposure regarding the formulation of pentavalent vaccine used during the period of transi-
tion from GSK to SII pentavalent vaccine in Kenya’s routine immunization program, although
such misclassification would have biased our comparison of abscess risk between the pentava-
lent vaccine formulations toward the null. If the observed association is not attributable to sam-
pling error or ascertainment bias, then it would have significant implications for vaccine policy
in Kenya and elsewhere in the developing world. The risk difference between pentavalent vac-
cine formulations is most interpretable in the Rarieda PBIDS site, where non-zero abscess
incidences were observed for both pentavalent vaccine products—there, the risk difference
between the 10-aliquot vial and the 2-aliquot vial pentavalent vaccine formulations was
roughly 1% (1.30% risk for 10-aliquot vial pentavalent vaccine minus 0.36% risk for 2-aliquot
vial pentavalent vaccine), suggesting that 1% of children receiving the 10-aliquot vial pentava-
lent vaccine may develop abscesses attributable to the new formulation. Abscesses in the Rar-
ieda PBIDS site were identified through active household surveillance which, as noted above,
could identify abscess events not severe enough to prompt a health facility visit. Nevertheless,
Kenya administers approximately 5 million doses of pentavalent vaccine per year, which, with
the 10-aliquot vial product, could be responsible for 50,000 unnecessary abscesses, some pro-
portion of which may be associated with more severe clinical manifestations, like bacteremia
and sepsis. The magnitude of the risk ratio across two sites suggests that the potential of con-
tamination of doses of the 10-aliquot vial pentavalent vaccine in Kenya should be further evalu-
ated and additional training on proper handling and administration of this pentavalent vaccine
should be considered. Inclusion of a preservative may not wholly counter the risk of contami-
nation in 10-aliquot vial vaccine presentations used in developing countries.
This study provides important lessons for vaccine safety monitoring in developing coun-
tries. The infrastructure for vaccine safety surveillance is often limited in the very settings that
are most in need of expanded access to immunizations. In the current study, even the combina-
tion of four field study sites in Kenya with existing surveillance capacity provided a study
power of only ~80% to detect a three-fold increased risk of injection site abscess, which is a rel-
atively common potential AEFI. Less frequent but more serious AEFI would be even more dif-
ficult to detect with existing surveillance systems. As new vaccines are introduced into GAVI
countries, the potential for undetected adverse events is considerable. In addition, the capacity
of national immunization programs and global vaccine policy bodies to refute spurious associa-
tions (e.g., autism and vaccines) is determined by the robustness of AEFI surveillance systems.
HDSS sites and similar health surveillance platforms in developing countries provide useful
frameworks for AEFI surveillance, but more such platforms are needed and specific effort and
resources should be allocated to develop effective AEFI surveillance programs in multiple sites.
The potential for breaks in sterile technique and vaccine-handling practices likely differs from
site to site and in different countries in Africa, so substantial additional experience and more
post-licensure observational studies will be needed to fully characterize risks associated with
use of preservative-free, multi-dose vial vaccine formulations such as PCV10 in developing
countries.
Conclusions
In summary, this Phase IV multisite study found no evidence to suggest that use of a 2-aliquot
vial, preservative-free formulation of PCV10 in Kenya’s routine immunization program was
associated with an increased risk of injection site abscesses, related to the second aliquot or
overall. The incidental observation of an increased risk of abscess associated with a change in
the formulation of the comparator vaccine (pentavalent) during the study period, while
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complicated, confirms the capacity of the VAEIK surveillance methods to detect relevant, clini-
cally important changes in the safety profile of vaccines administered in Kenya’s routine
immunization program and provides context for the findings regarding PCV10.
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